Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Prime Minister Narendra Modi on Saturday met seven Indian COVID-19 vaccine manufacturers just days after the country reached the landmark of administering 100 crore vaccine doses, news agency PTI reported.
Representatives from seven vaccine makers including Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Zydus Cadila attended the meeting with PM Modi.
Union Health Minister Mansukh Mandaviya and Union Minister of State for Health Bharati Pravin Pawar were also present in the meeting as well.
During the meeting, PM Modi reportedly discussed various issues including furthering the vaccine research
The cumulative COVID-19 vaccine doses administered in the country has exceeded 101.30 crore, according to the Health Ministry data updated on Saturday morning
India on October 21 achieved a major milestone in its vaccination programme as the vaccine doses administered surpassed the 100-crore mark, resulting in celebrations across the country
More than 75 per cent of India&rsquo;s adult population has received at least one dose of Covid-19 vaccine, while over 31 per cent adults have been administered both doses, according to health ministry officials.

After 'billion jab' feat, PM Modi meets 7 Indian COVID vaccine makers

PM Modi met seven Indian Covid-19 vaccine manufacturers just days after the country reached the landmark of administering 100 crore vaccine doses

PM Modi met seven Indian Covid-19 vaccine manufacturers
Meeting comes after the historic&nbsp;100 crore vaccine doses feat
Representatives from SII,&nbsp;Bharat Biotech, Dr Reddy's&nbsp;present
Health Minister Mansukh Mandaviya&nbsp;present at the meeting&nbsp;
PM Modi&nbsp;discussed furthering the vaccine research, reports suggested
India on October 21 achieved a major milestone in its vaccination programme
More than 75% population received at least one dose, 31% got both doses
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;

More than 75% of India&rsquo;s adult population has received at least one dose of Covid-19 vaccine, while over 31% have been administered both doses, according to health ministry officials.

Prime Minister Narendra Modi on Saturday met seven Indian COVID-19 vaccine manufacturers just days after the country reached the landmark of administering 100 crore vaccine doses, news agency PTI reported.
Representatives from seven vaccine makers including Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Zydus Cadila attended the meeting with PM Modi.
Union Health Minister Mansukh Mandaviya and Union Minister of State for Health Bharati Pravin Pawar were also present in the meeting as well.
During the meeting, PM Modi reportedly discussed various issues including furthering the vaccine research
The cumulative COVID-19 vaccine doses administered in the country has exceeded 101.30 crore, according to the Health Ministry data updated on Saturday morning
India on October 21 achieved a major milestone in its vaccination programme as the vaccine doses administered surpassed the 100-crore mark, resulting in celebrations across the country
More than 75 per cent of India&rsquo;s adult population has received at least one dose of Covid-19 vaccine, while over 31 per cent adults have been administered both doses, according to health ministry officials.

The Sputnik V vaccine, which was the third vaccine to get approval in India, was soft launched on a pilot basis earlier on May 14. 

Sputnik V's commercial roll-out in India in the next few weeks: Dr Reddy's

Sputnik V Covid-19&nbsp;vaccine's commercial roll out in India will go on as planned&nbsp;over the next few weeks, says Dr Reddy's

Commercial roll out of Sputnik V in India in the next few weeks
Dr Reddy&rsquo;s&nbsp;assured to strengthen Sputnik V supply nationwide
Dr Reddy's:&nbsp;ongoing soft launch and&nbsp;ramp-up not put on hold
Sputnik V was the third Covid vaccine to get approval in India
The Russian vaccine was soft launched on a pilot basis on May 14
Soft launch of Sputnik V has been done in over 50 cities in India
Studies have shown Sputnik V is effective against new Covid variants

Neither the ongoing soft commercial launch nor work towards its ramp-up in India have been put on hold, says Dr. Reddy's Laboratories.

Amid apprehensions over the commercial rollout of Russian <a href="https://www.editorji.com/story/sputnik-v-what-you-need-to-know-about-the-russian-vaccine-1618243022603" target="_blank">Covid-19 vaccine Sputnik V in India</a>, Dr Reddy&rsquo;s Laboratories has assured to strengthen the commercial roll-out of Sputnik V in the coming weeks.
In a statement, Dr Reddy's said, neither the ongoing soft commercial launch nor work towards its ramp-up in India have been put on hold.
The Sputnik V vaccine, which was the third vaccine to get approval in India, was soft launched on a pilot basis earlier on May 14. The nationwide soft launch of Sputnik V has been done in over 50 cities and towns across the country.
Meanwhile, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), who are behind the formulation of Sputnik V, on Monday said that individuals vaccinated with Sputnik V will be protected against the new variants of SARS-CoV-2, including the Delta variant, first detected in India.
&nbsp;
Also watch |&nbsp;<a href="https://www.editorji.com/story/delta-strain-8-times-less-sensitive-to-covid-vaccine-antibodies-study-1625493274369" target="_blank">Delta strain 8 times less sensitive to Covid vaccine antibodies: study</a>

Sputnik V pilot is in it's last leg and is ready to be expanded to other cities after Mumbai, Delhi and Hyderabad as per Dr Reddy's&nbsp;Lab which has currently&nbsp;soft-launched Russia's COVID-19 vaccine.A press release from Dr Reddy's said&nbsp;CoWIN&nbsp;registration for the Russian vaccine will be available as soon as they commercially&nbsp;launch the jab. The current pilot project&nbsp;allowed Dr Reddy's to test the cold storage arrangements of -18C temperature in the cities as well as the logistic chain for the vaccine.&nbsp;

Sputnik V pilot in final leg; Dr Reddy's gears for commercial launch

Sputnik V pilot is in it's last leg and is ready to be expanded to other cities after Mumbai, Delhi and Hyderabad as per Dr Reddy's&nbsp;Lab which has currently&nbsp;soft-launched Russia's COVID-19 vaccine. A press release from Dr Reddy's said&nbsp;CoWIN&nbsp;registration for the Russian vaccine will be available as soon as they commercially&nbsp;launch the jab. The current pilot project&nbsp;allowed Dr Reddy's to test the cold storage arrangements of -18C temperature in the cities as well as the logistic chain for the vaccine.&nbsp;

Sputnik V pilot is in it's last leg and is ready to be expanded to other cities after Mumbai, Delhi and Hyderabad as per Dr Reddy's&nbsp;Lab which has currently&nbsp;soft-launched Russia's COVID-19 vaccine. A press release from Dr Reddy's said&nbsp;CoWIN&nbsp;registration for the Russian vaccine will be available as soon as they commercially&nbsp;launch the jab. The current pilot project&nbsp;allowed Dr Reddy's to test the cold storage arrangements of -18C temperature in the cities as well as the logistic chain for the vaccine.&nbsp;

The Russian vaccine against Covid-19, Sputnik V, is likely to be available at Indraprastha Apollo Hospital in Delhi from Tuesday, according to a report. The Sputnik V rollout will depend on the number of consignments received by the hospital, news agency ANI has reported.
The Centre has fixed the price of the vaccine at ₹1,145 per dose.
ANI also reported that Sputnik V was administered to employees of Dr Reddy's Laboratories at Delhi's Indraprastha Apollo Hospital on Sunday. As many as 1000 doses of Sputnik V reached the Apollo Hospital and 179 doses were administered to the Dr Reddy's Laboratories&rsquo; employees.
Dr Reddy's Laboratories has partnered with the Russian Direct Investment Fund, which globally markets the Covid-19 vaccine, for the rollout of the two-dose vaccine in India.
Sputnik V claimed to have the highest efficacy rate at 91.6 per cent&mdash;Moderna and Pfizer vaccines also have an efficacy of over 90 per cent.

Sputnik V likely to be available in Delhi from today: report

The Russian vaccine against Covid-19, Sputnik V, is likely to be available at Indraprastha Apollo Hospital in Delhi from Tuesday, according to a report.

The Russian vaccine against Covid-19, Sputnik V, is likely to be available at Indraprastha Apollo Hospital in Delhi from Tuesday, according to a report. The Sputnik V rollout will depend on the number of consignments received by the hospital, news agency ANI has reported.
The Centre has fixed the price of the vaccine at ₹1,145 per dose.
ANI also reported that Sputnik V was administered to employees of Dr Reddy's Laboratories at Delhi's Indraprastha Apollo Hospital on Sunday. As many as 1000 doses of Sputnik V reached the Apollo Hospital and 179 doses were administered to the Dr Reddy's Laboratories&rsquo; employees.
Dr Reddy's Laboratories has partnered with the Russian Direct Investment Fund, which globally markets the Covid-19 vaccine, for the rollout of the two-dose vaccine in India.
Sputnik V claimed to have the highest efficacy rate at 91.6 per cent&mdash;Moderna and Pfizer vaccines also have an efficacy of over 90 per cent.

The first batch of 10,000 doses of 2DG medicine for treating Covid-19 patients would be launched early next week, Defence Research and Development Organisation officials informed on Friday.
The drug manufacturers are working on ramping up the production of the medicine for future use. &nbsp;Production of the 2-DG drug on a large-scale will start soon in Hyderabad and at other centres too.
The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Hyderabad-based Dr Reddy's Laboratories.

DRDO’s 2DG medicine for treating Covid patients to be launched early next week

10,000 doses of 2-DG drug to be launched early next week
Developed by DRDO's&nbsp;INMAS&nbsp;in collaboration with&nbsp;Dr Reddy's
2DG drug production on large-scale to start soon in Hyderabad

The first batch of 10,000 doses of 2DG medicine for treating Covid-19 patients would be launched early next week, Defence Research and Development Organisation officials informed on Friday.
The drug manufacturers are working on ramping up the production of the medicine for future use. &nbsp;Production of the 2-DG drug on a large-scale will start soon in Hyderabad and at other centres too.
The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Hyderabad-based Dr Reddy's Laboratories.

While Russia's Sputnik V vaccine is already available in India, Dr Reddys&nbsp;Laboratories CEO&nbsp;Deepak&nbsp;Sapra&nbsp;has said that his company is now trying to seek regulatory approval for the single-dose Sputnik V Light vaccine. The Hyderabad-based pharma&nbsp;giant has also partnered with the Russian Direct Investment Fund (RDIF) to bring the 2 dose vaccine to India. Sapra&nbsp;who confirmed that the Clinical trials of the single-dose vaccine are being conducted in Russia&nbsp;added&nbsp;that Sputnik Light's single shot will be able to give 80% efficacy. Hoping that the vaccine is approved for use in India, he further said that Sputnik Light will be a shot in the arm for the country's vaccination program. Moreover, the CEO&nbsp;of the company also assured that Sputnik V which is currently being administered in a few private hospitals of India will&nbsp;be more affordable as the production starts in India.&nbsp;

Working with regulators to bring Sputnik Light to India: Dr. Reddy's Laboratories

Dr Reddy's&nbsp;CEO:&nbsp;&nbsp;seeking regulatory approval for Sputnik Light
Sapra&nbsp;said single-dose Sputnik Light vaccine gives 80% efficacy
Sapra: Sputnik Light a shot in the arm for India's vaccination program

Dr Reddy's&nbsp;Laboratories CEO&nbsp;Deepak&nbsp;Sapra&nbsp;has said that his company is trying to seek regulatory approval for the single-dose Sputnik V Light vaccine in India. &nbsp;Sapra&nbsp;who confirmed that the Clinical trials of the single-dose vaccine are being conducted in Russia&nbsp;added&nbsp;that Sputnik Light's single shot will be able to give 80% efficacy. He further said that Sputnik Light will be a shot in the arm for the country's vaccination program.&nbsp;NITI Aayog's&nbsp;Dr VK Paul said at a press conference earlier this month that they are investigating&nbsp;Russian Direct Investment Fund's (RDIF) claim that the first dose of Sputnik Light is enough.

Sputnik V Price in India: Good news in the fight against Covid 19, Russian vaccine Sputnik V has finally come into the Indian market. 

Sputnik V Price in India | Sputnik V is here, first vaccines administered in Hyderabad

Dr Reddy's&nbsp;says&nbsp;first jab of the Russian vaccine has been administered in Hyderabad on Friday.&nbsp;Dr Reddys&nbsp;has&nbsp;set&nbsp;Sputnik V vaccine price at Rs ₹995/dose for the imported doses.&nbsp;

Sputnik V is finally here, first doses given 

<ul>
<li>First dose of Sputnik V administered in Hyderabad&nbsp;</li>
<li>Pricing for imported doses of Sputnik V set at Rs 995/dose</li>
<li>Dr Reddy's&nbsp;expects price of Sputnik V to come down in coming weeks</li>
<li>Sputnik V is being imported by Hyderabad based Dr Reddy's&nbsp;Labs</li>
</ul>

Good news in the fight against<a href="https://www.editorji.com/covid-19" target="_blank"> Covid&nbsp;19</a>, Russian vaccine Sputnik V has finally come into the Indian market. Two weeks after the&nbsp;1.5 lakh first doses arrived in Hyderabad, RDIF&nbsp;partner Dr Reddy's confirmed that the first jab of the Russian vaccine was administered in Hyderabad on Friday.&nbsp;
Also Read | <a href="https://www.editorji.com/story/know-your-vaccines-how-do-sputnik-v-covaxin-and-covishield-work-1618306290653" target="_blank">Know your vaccines: How do Sputnik V, Covaxin and Covishield work?</a>
Dr Reddys&nbsp;has&nbsp;set&nbsp;<a href="https://www.editorji.com/story/sputnik-v-what-you-need-to-know-about-the-russian-vaccine-1618243022603" target="_blank">Sputnik V vaccine</a> price at Rs ₹995/dose for the imported doses.&nbsp;Dr Reddy&rsquo;s&nbsp;has said&nbsp;pricing of RDIF&rsquo;s COVID vaccine Sputnik V is expected to go lower once its domestic production begins.&nbsp; This is a big boost for the inoculation drive when&nbsp; India is recording over 3 lakh Covid-19 cases every day and is struggling for vaccines as many states, private and government facilities run out of doses.
Also Read | <a href="https://www.editorji.com/story/russia-s-sputnik-v-vaccine-to-be-available-in-market-by-next-week-govt-1620915124326" target="_blank">Russia's Sputnik V vaccine to be available in market by next week: Govt</a>

Russian Covid-19 vaccine Sputnik V will be available for use in India next month with imports coming in from Russia. 

Covid-19: Russia's Sputnik vaccine to be rolled out in India next month

Russian Covid-19 vaccine Sputnik V will be available for use in India next month with imports coming in from Russia, says report

Covid-19: Sputnik vaccine to be rolled out in India next month

Russian Covid-19 vaccine Sputnik V will be available for use in India next month with imports coming in from Russia. Local manufacturing will kick in from the July-September quarter, The Times of India has reported quoting top officials of Dr Reddy&rsquo;s Laboratories. Sputnik V received emergency use authorisation from the govt earlier this week. Dr Reddy&rsquo;s has a contract with the Russian Direct Investment Fund for distributing 125 million doses of Sputnik V vaccine. The vaccine has proved to be 91.6% effective in clinical trials and is given in 2 doses in 21 days.

Russian <a href="https://www.editorji.com/story/sputnik-v-what-you-need-to-know-about-the-russian-vaccine-1618243022603" target="_blank">Covid-19 vaccine Sputnik V</a> will be available for use in India next month with imports coming in from Russia. Local manufacturing will kick in from the July-September quarter, The Times of India has reported quoting top officials of Dr Reddy&rsquo;s Laboratories.
Sputnik V received emergency use authorisation from the govt earlier this week. Dr Reddy&rsquo;s has a contract with the Russian Direct Investment Fund for distributing 125 million doses of <a href="https://www.editorji.com/story/850-million-doses-of-sputnik-v-covid-vaccine-annually-limited-shots-by-month-end-1618298567193" target="_blank">Sputnik V vaccine</a>. The vaccine has proved to be 91.6% effective in clinical trials and is given in 2 doses in 21 days.
Also Read | <a href="https://www.editorji.com/story/know-your-vaccines-how-do-sputnik-v-covaxin-and-covishield-work-1618306290653" target="_blank">Know your vaccines: How do Sputnik V, Covaxin and Covishield work?</a>

India gives go ahead for trials of Russia's Sputnik vaccine

India's drug controller has given a go ahead to Dr Reddys Laboratories and Russian Direct Investment Fund for the phase 2 and 3 human clinical trial for Russia's Sputnik V Covid vaccine&nbsp;

India's drug controller has given a go ahead to Dr Reddys Laboratories and Russian Direct Investment Fund for the phase 2 and 3 human clinical trial for Russia's Sputnik V Covid vaccine in India. The Hyderabad-based drug maker said in a press release that this will be a multi-center and randomised controlled study. Earlier in September, Dr&nbsp;Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr.Reddys upon regulatory approval in India.

India's drug controller has given a go ahead to Dr Reddys Laboratories and Russian Direct Investment Fund for the phase 2 and 3 human clinical trial for Russia's Sputnik V Covid vaccine in India. The Hyderabad-based drug maker said in a press release that this will be a multi-center and randomised controlled study, which will include safety and immunogenicity study. Earlier in September, Dr&nbsp;Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr.Reddys upon regulatory approval in India.

dr reddys laboratories

Categories